Mechanisms underlying and medical management of L-Dopa-associated motor complications

Journal of Neural Transmission

Volumn 118, Issue 12, 2011, Pages 1659-1660

  Gerlach, Manfred ^a   Riederer, Peter ^a   Scheller, Dieter ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; AMANTADINE; AMPA RECEPTOR ANTAGONIST; APOMORPHINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE 1 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; LEVODOPA; METABOTROPIC RECEPTOR ANTAGONIST; MRZ 8676; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OPIATE AGONIST; OPIATE ANTAGONIST; ROTIGOTINE; SEROTONIN 1A AGONIST; SEROTONIN 1B AGONIST; SEROTONIN 2A ANTAGONIST; UNCLASSIFIED DRUG;

BASAL GANGLION; CLINICAL PRACTICE; CONTINUOUS INFUSION; DRUG DELIVERY SYSTEM; DYSKINESIA; EDITORIAL; GENE EXPRESSION; HUMAN; INTRACELLULAR SIGNALING; INVOLUNTARY MOVEMENT; LEARNING; MOTOR DYSFUNCTION; PRIORITY JOURNAL; STIMULATION;

ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA;

EID: 84855171273     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-011-0728-0     Document Type: Editorial

References (11)

1. B Boroojerdi HM Wolff M Braun DK Scheller 2010 Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome Drugs Today (Barc) 46 7 483 505 10.1358/dot.2010.46.7.1463530 1:STN:280: DC%2BC3cjisVKjsg%3D%3D
2. TN Chase 1998 The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease Drugs 55 S1 1 9 9483164 10.2165/00003495-199855001-00001 (Pubitemid 28051032)
3. Dekundy A, Gravius A, Hechenberger M, Pietraszek M, Nagel J, Tober C, van der Elst M, Mela F, Parsons CG, Danysz W (2011). Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on l-DOPA-induced dyskinesia. J Neural Transm 118(12). doi: 10.1007/s00702-010-0526-0
4. 1A receptors in levodopa-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. J Neural Transm 118(12). doi: 10.1007/s00702-010-0571-8
5. Gerlach M, Beck J, Riederer P, van den Buuse M (2011b) Flibanserin attenuates l-DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease. J Neural Transm 118(12). doi: 10.1007/s00702-010-0570-9
6. Grünblatt E, Schmidt WJ, Scheller DKA, Riederer P, Gerlach M (2011) Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats. J Neural Transm 118(12). doi: 10.1007/s00702-010-0552-y
7. Iravani MM, Jenner P (2011) Mechanisms underlying the onset and expression of levodopa induced dyskinesia and their pharmacological manipulation. J Neural Transm 118(12). doi: 10.1007/s00702-011-0698-2
8. JJ Jankovic 2005 Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations Mov Disord 20 Suppl 11 S11 S16 15822109 10.1002/mds.20458 (Pubitemid 40846906)
9. Jenner P, McCreary AC, Scheller DKA (2011) Continuous drug delivery in early and late stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression. J Neural Transm 118(12). doi: 10.1007/s00702-011-0703- 9
10. T Müller H Russ 2006 Levodopa, motor fluctuations and dyskinesia in Parkinson's disease Expert Opin Pharmacol 7 1715 1730 10.1517/14656566.7.13.1715
11. E Wolf K Sepppi R Katzenschlager, et al. 2010 Long-term antidyskinetic efficacy of amantadine in Parkinson's disease Mov Disord 25 1357 1363 20198649 10.1002/mds.23034